DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Entinostat is an investigational drug.
There have been 64 clinical trials for Entinostat. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2014.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Syndax Pharmaceuticals, National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.
There are one hundred and fifty-four US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Entinostat
|Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread||National Cancer Institute (NCI)||Phase 1|
|BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)||National Cancer Institute (NCI)||Phase 1|
|Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer||UNC Lineberger Comprehensive Cancer Center||Phase 2|
Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Entinostat||Start Trial||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||Start Trial|
|Entinostat||Start Trial||Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III||Frequency Therapeutics, Inc. (Woburn, MA)||Start Trial|
|Entinostat||Start Trial||Liposomal compositions of epoxyketone-based proteasome inhibitors||Onyx Therapeutics, Inc. (Thousand Oaks, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Entinostat||World Intellectual Property Organization (WIPO)||WO2015148714||2034-03-25||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|